首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >The Value of Safflower Yellow Injection for the Treatment of Acute Cerebral Infarction: A Randomized Controlled Trial
【24h】

The Value of Safflower Yellow Injection for the Treatment of Acute Cerebral Infarction: A Randomized Controlled Trial

机译:红花黄注射液治疗急性脑梗死的价值:一项随机对照试验

获取原文
           

摘要

Background. Safflower Yellow Injection has been reported as a treatment for acute cerebral infarction in recent studies in China. However, there is a lack of availability of the evidence for the efficacy and safety of Safflower Yellow Injection for the treatment of acute ischemic stroke. So we investigated the effects of Safflower Yellow Injection for the treatment of acute cerebral infarction.Method. All subjects were randomly divided into Safflower Yellow Injection group given Safflower Yellow Injection (80 mg) and control group given placebo (0 mg) injection by intravenous drop once daily for 14 days. National Institute of Health Stroke Scale (NIHSS); hemorheological detection; coagulation function; and serum inflammatory markers, tumor necrosis factor-alpha (TNF-α), interleukin-1β(IL-1β), and interleukin-6 (IL-6), were used to investigate the effects before and 14 days after the treatment.Results. The scores of NIHSS were decreased on day 7 and day 14 after treatment. The hemorheological index of RBC deformation and RBC aggregation were significantly improved, prothrombin time (PT) increased, and fibrinogen (FIB) and TNF-α, IL-1β, and IL-6 were decreased in patients treated with Safflower Yellow injection on day 14 after treatment (P<0.05).Conclusion. Data suggests that Safflower Yellow Injection therapy may be beneficial for acute cerebral infarction.
机译:背景。在中国最近的研究中已经报道了红花黄注射液作为一种治疗急性脑梗死的方法。然而,缺乏关于红花黄注射液治疗急性缺血性中风的有效性和安全性的证据。因此,我们研究了红花黄注射液治疗急性脑梗死的疗效。所有受试者随机分为红花黄注射液组,红花黄注射液(80μg)和对照组,安慰剂(0μmg)注射,静脉滴注一次,共14天。美国国立卫生研究院卒中量表(NIHSS);血液流变学检测;凝血功能使用血清炎症标记物,肿瘤坏死因子-α(TNF-α),白细胞介素-1β(IL-1β)和白细胞介素-6(IL-6)来研究治疗前后的效果。 。治疗后第7天和第14天,NIHSS评分降低。第14天用红花黄注射液治疗的患者的RBC变形和RBC聚集的血液流变学指标显着改善,凝血酶原时间(PT)增加,纤维蛋白原(FIB)和TNF-α,IL-1β和IL-6降低治疗后(P <0.05)。结论。数据表明,红花黄注射液治疗可能对急性脑梗死有益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号